Impact of total thyroidectomy on quality of life at 6 months: the prospective ThyrQoL multicentre trial.


Journal

European journal of endocrinology
ISSN: 1479-683X
Titre abrégé: Eur J Endocrinol
Pays: England
ID NLM: 9423848

Informations de publication

Date de publication:
02 2020
Historique:
received: 21 07 2019
accepted: 03 12 2019
pubmed: 6 12 2019
medline: 17 3 2020
entrez: 6 12 2019
Statut: ppublish

Résumé

This study is to determine the impact of complications after total thyroidectomy on health-related quality of life (HR-QoL) and to identify significant predictive factors of HR-QoL changes. HR-QoL is usually impaired in patients with thyroid diseases compared to the general population. Thyroidectomy is largely performed in the case of benign thyroid benign and can be associated with long-term complications (vocal cord palsy, hypoparathyroidism). The prospective ThyrQoL multicenter trial (NCT02167529) included 800 patients who underwent total thyroidectomy for benign or malignant non-extensive disease in seven French referral hospitals between 2014 and 2016. HR-QoL was assessed using the MOS 36-item short form health survey (SF-36) self-questionnaire with a 6-month follow-up. We observed a significant improvement of HR-QoL 6 months after surgery (P < 0.0001). Postoperative complications were associated with a non-significant impairment of HR-QoL. In multivariable analysis, Graves' disease was associated with a significant improvement of HR-QoL (OR = 2.39 [1.49; 3.84]) and thyroid malignant disease with an impairment of HR-QoL (OR = 1.44 [0.99; 2.08]) after thyroidectomy. We observed a significant improvement of HR-QoL 6 months after total thyroid surgery for benign thyroid disease.

Identifiants

pubmed: 31804967
doi: 10.1530/EJE-19-0587
pii: EJE-19-0587
doi:
pii:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

195-205

Auteurs

E Mirallié (E)

Chirurgie Cancérologique, Digestive et Endocrinienne, Hôtel Dieu, CHU Nantes, Place Alexis Ricordeau, Nantes Cedex 1, France.

F Borel (F)

Chirurgie Cancérologique, Digestive et Endocrinienne, Hôtel Dieu, CHU Nantes, Place Alexis Ricordeau, Nantes Cedex 1, France.

C Tresallet (C)

Chirurgie Générale, Viscérale et Endocrinienne, Hôpital Pitié-Salpêtrière, AP-HP, Sorbonne Universités Pierre et Marie Curie (Paris 6), Paris, France.

A Hamy (A)

CHU Angers, Chirurgie Digestive et Endocrinienne, Angers Cedex 09, France.

M Mathonnet (M)

Chirurgie Digestive, Générale et Endocrinienne, CHU de Limoges - Hôpital Dupuytren, Limoges Cedex, France.

J C Lifante (JC)

Chirurgie Générale, Endocrinienne, Digestive et Thoracique, Centre Hospitalier Lyon-Sud, Pierre Bénite Cedex, France.

L Brunaud (L)

Service de Chirurgie Digestive, Hépato-Biliaire, et Endocrinienne, CHU Nancy - Hôpital de Brabois, Nancy, France.

F Menégaux (F)

Chirurgie Générale, Viscérale et Endocrinienne, Hôpital Pitié-Salpêtrière, AP-HP, Sorbonne Universités Pierre et Marie Curie (Paris 6), Paris, France.

J B Hardouin (JB)

UMR INSERM 1246-SPHERE, Université de Nantes, Université de Tours-Institut de Recherche en santé 2, Nantes, France.
Plateforme de Méthodologie et de Biostatistique - DRCi - CHU de Nantes, Nantes, France.

C Blanchard (C)

Chirurgie Cancérologique, Digestive et Endocrinienne, Hôtel Dieu, CHU Nantes, Place Alexis Ricordeau, Nantes Cedex 1, France.
Institut du Thorax, INSERM, CNRS, UNIV Nantes, Nantes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH